Deletion of CD274 (which encodes PD-L1) in T cells enhances adaptive tumour immunity and activates TAMs, indicating that the use of anti-PD-1/PD-L1 inhibitors will enhance immunity in tumours with a high density of CD4+FoxP3−PD-L1+ T cells31. Here, PDCD1 is linked to neoplasm.